TC-510 is under clinical development by TCR2 Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TC-510’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TC-510 is under development for the treatment of solid tumors such as ovarian cancer, pancreatic cancer, colorectal cancer, malignant pleural mesothelioma and triple negative breast cancer. It acts by targeting mesothelin. The therapeutic candidate comprises T cells genetically modified with lentivirus vector to express T cell receptor (TCR) co-expressing PD-1 switch receptor. It acts by targeting mesothelin. The therapeutic candidate is being developed based on TruC (TCR fusion construct) technology. it is administered through parenteral route.
TCR2 Therapeutics overview
TCR2 Therapeutics is an immuno-oncology company that develops novel therapies for the treatment of various cancers. The company develops a pipeline of TRuC program for solid and hematologic cancers. It also develops TC-210 TRuC-T cell program and CD19-TRuC-T cell program. The company’s TC-210 TRuC-T cell program targets mesothelin-expressing solid tumors including ovarian, pancreatic, lung, mesothelioma, and cholangiocarcinoma. It also develops TRuC variants with other elements which are designed to maintain the immunotherapeutic response. It partners with other pharmaceutical companies and hospitals to develop novel therapies. TCR2 Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of TC-510’s drug-specific PTSR and LoA scores, buy the report here.